Business
Mercy BioAnalytics Announces $59 Million Series B Financing to Advance Early Cancer Detection Programs
Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Fund, American Cancer Society BrightEdge and iSelect Fund, as well as funds committed to women's health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital. The round also included signifi
About this update from Labcorp Holdings Inc.
[{"type":"text","content":"WALTHAM, Mass., Sept. 3, 2025 /PRNewswire/ -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced the closing of a $59 million series B financing. The round was co-led by Novalis and Sozo Ventures, with participation from Perceptive Xontogeny Venture Fund, American Cancer Society BrightEdge and iSelect Fund, as well as funds committed to women's health and leadership including Portfolia, Avestria Ventures, and Mindshift Capital. The round also included significant participation from strategic investors including Hologic, Bruker Scientific, and Labcorp.","length":644,"tagName":"p"},{"type":"image","alt":"Mercy BioAnalytics (PRNewsfoto/Mercy BioAnalytics)","displaySize":"","headline":null,"caption":"Mercy BioAnalytics (PRNewsfoto/Mercy BioAnalytics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https://media.zenfs.com/en/prnewswire.com/4ee0e96538779c5e48b88c8d50192afe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0PKuiPEDenDZXdUFzXYNeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4ee0e96538779c5e48b88c8d50192afe","width":400,"height":225}},"href":"https://mma.prnewswire.com/media/2395693/mercy_logo_color_resized_cropped_4K_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Coincident with the financing, Mercy is pleased to welcome Rob Freelen to the Board of Directors. A Managing Director and investment partner at Sozo Ventures, Mr. Freelen brings a wealth of experience as a seasoned Director, successful entrepreneur and former executive at Silicon Valley Bank. "Sozo is proud to co-lead this round and help usher in a new generation of cancer diagnostics with the potential to save lives at scale."","length":441,"tagName":"p"},{"type":"text","content":"The financing will support the commercialization of Mercy's blood-based ovarian cancer test portfolio, designed to detect ovarian cancer at earlier, more treatable stages across multiple indications. The Mercy Halo ovarian cancer screening test exhibits unprecedented sensitivity and specificity for the detection of pre-clinical high grade serous ovarian carcinoma in post-menopausal women based on a blinded evaluation of samples from a randomized controlled tr...